Early Release

Early Release / Review Article

Prof. Dr. Abdülkadir Noyan: Professional and Academic Aspects

Turhan Ada

Most Read

  1. Pneumococcal Vaccine as One of the Immunization Coverage Targets for Adulthood Vaccines: A Consensus Report of the Study Group for Adult Immunization of the Turkish Society of Clinical Microbiology and Infectious Diseases
  2. Does Hepatitis B Affect Erectile Dysfunction and Lower Urinary Tract Symptoms?
  3. HIV Infection in Turkey: How Close Are We to the Target?
  4. Evaluation of HBeAg-Negative Chronic Hepatitis B Patients Who Had Undergone Liver Biopsy in Accordance With the Guidelines
  5. Diagnosis, Treatment and Prevention of Diabetic Foot Wounds and Infections: Turkish Consensus Report
  6. When to Stop Antiviral Therapy in Chronic Hepatitis B
  7. Mycoplasma hominis and Ureaplasma urealyticum: Their Role in Urogenital System Infections and Retrospective Evaluation of Antibiotic Resistance Rates
  8. Crimean-Congo Haemorrhagic Fever: Treatment and Use of Ribavirin
  9. Modern Diagnostic Methods Used in Bacteriology: Rapid and Effective
  10. Analysis of HIV/AIDS-Related Stigma and Discrimination in Turkey: Results of the People Living With HIV Stigma Index

Volume 33, Issue 2

Original Article

Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella spp. in Community-Acquired Urinary Tract Infections and Their Antimicrobial Resistance

Arzu Şenol
Affiliations
  • Elazığ Fethi Sekin Şehir Hastanesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Elazığ, Türkiye
,
Yusuf Yakupoğulları
Affiliations
  • İnönü Üniversitesi, Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, Malatya, Türkiye
,
Feray Ferda Şenol
Affiliations
  • Elazığ Fethi Sekin Şehir Hastanesi, Tıbbi Mikrobiyoloji Laboratuvarı, Elazığ, Türkiye
  • Enterobacteriaceae
  • Escherichia coli
  • Klebsiella spp
  • urinary tract infection

Objective: Production of extended-spectrum β-lactamases (ESBLs) is the most important antimicrobial resistance mechanism among Gram-negative pathogens. In this study, ESBL frequency and antimicrobial resistance of Escherichia coli and Klebsiella spp. isolated from community-acquired urinary tract infections (UTIs) are investigated.

Methods: In this retrospective cross-sectional study, ESBL rates and the results of antimicrobial susceptibility tests were determined for E. coli and Klebsiella spp. grown in the urine cultures of 520 patients with community-acquired UTI, and the changes in the antimicrobial resistance rates of the isolates were compared in terms of ESBL production.

Results: E. coli had grown in 220 samples and Klebsiella spp. in 38 samples. ESBL production frequencies of the isolates were found as 40% and 47.4%, respectively, and the rate of carbapenem resistance was found as 3.1%. Among the isolates, the highest resistance was found for amoxicillin-clavulanate (46%), ciprofloxacin (44.9%), and ceftriaxone (42.2%), while the lowest resistance was found for colistin (0.3%), fosfomycin (1.5%), amikacin (3.1%), and nitrofurantoin (4.2%). In ESBL-producers, significantly higher resistance was found for all antibiotics studied, except colistin, nitrofurantoin and fosfomycin.

Conclusions: In this study, it was shown that almost half of the community-acquired isolates were ESBL-producers, and these isolates had acquired resistance against many antimicrobials including the last resorts such as carbapenems and colistin. To reduce the progress of resistance rates in E. coli and Klebsiella spp. which are the most common pathogens in community-acquired UTIs, their therapies should be planned according to the results of susceptibility tests as much as possible.

Klimik Dergisi. 2020; 33(2): 163-8.

Cite this article as: Şenol A, Yakupoğulları Y, Şenol FF. [Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella spp. in community-acquired urinary tract infections and their antimicrobial resistance]. Klimik Derg. 2020; 33(2): 163-8. Turkish.

  • 163-168
  • 10.5152/kd.2020.34
  • August 28, 2020
  • 1177
  • 560
Download as PDF
  • This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. CC BY-NC
Volume 37, Issue 4 Volume 37, Issue 3 Volume 37, Issue 2 Volume 37, Issue 1 Volume 36, Issue 4 Volume 36, Supplement 1 Volume 36, Issue 3 Volume 36, Issue 2 Volume 36, Issue 1 Volume 35, Issue 4 Volume 35, Issue 3 Volume 35, Issue 2 Volume 35, Issue 1 Volume 34, Issue 3 Volume 34, Issue 2 Volume 34, Issue 1 Volume 33, Issue 3 Volume 33, Issue 2 Volume 33, Issue 1 Volume 32, Issue 3 Volume 32, Supplement 1 Volume 32, Supplement 2 Volume 32, Issue 2 Volume 32, Issue 1 Volume 31, Issue 3 Volume 31, Issue 2 Volume 31, Supplement 1 Volume 31, Issue 1 Volume 30, Issue 3 Volume 30, Issue 2 Volume 30, Supplement 1 Volume 30, Issue 1 Volume 29, Issue 3 Volume 29, Issue 2 Volume 29, Issue 1 Volume 28, Supplement 1 Volume 28, Issue 3 Volume 28, Issue 2 Volume 28, Issue 1 Volume 27, Supplement 1 Volume 27, Issue 3 Volume 27, Issue 2 Volume 27, Issue 1 Volume 26, Issue 3 Volume 26, Supplement 1 Volume 26, Issue 2 Volume 26, Issue 1 Volume 25, Issue 3 Volume 25, Issue 2 Volume 25, Issue 1 Volume 24, Issue 3 Volume 24, Issue 2 Volume 24, Issue 1 Volume 23, Issue 3 Volume 23, Issue 2 Volume 23, Issue 1 Volume 22, Issue 3 Volume 22, Issue 2 Volume 22, Issue 1 Volume 21, Issue 3 Volume 21, Supplement 2 Volume 21, Supplement 1 Volume 21, Issue 2 Volume 21, Issue 1 Volume 20, Issue 3 Volume 20, Supplement 2 Volume 20, Issue 2 Volume 20, Issue 1 Volume 20, Supplement 1 Volume 19, Issue 3 Volume 19, Issue 2 Volume 19, Issue 1 Volume 18, Issue 3 Volume 18, Supplement 1 Volume 18, Issue 2 Volume 18, Issue 1 Volume 17, Issue 3 Volume 17, Issue 2 Volume 17, Issue 1 Volume 16, Issue 3 Volume 16, Issue 2 Volume 16, Issue 1 Volume 1, Supplement 1 Volume 15, Issue 3 Volume 15, Issue 2 Volume 15, Issue 1 Volume 14, Issue 3 Volume 14, Issue 2 Volume 14, Issue 1 Volume 13, Issue 3 Volume 13, Issue 2 Volume 13, Supplement 1 Volume 13, Issue 1 Volume 12, Issue 3 Volume 12, Issue 2 Volume 12, Issue 1 Volume 11, Issue 3 Volume 11, Issue 2 Volume 11, Supplement 1 Volume 11, Issue 1 Volume 10, Issue 3 Volume 10, Issue 2 Volume 10, Issue 1 Volume 9, Issue 3 Volume 9, Issue 2 Volume 9, Issue 1 Volume 8, Issue 3 Volume 8, Issue 2 Volume 8, Issue 1 Volume 6, Issue 3 Volume 7, Issue 1 Volume 7, Issue 2 Volume 7, Issue 3 Volume 4, Issue 3 Volume 5, Issue 1 Volume 5, Issue 2 Volume 5, Issue 3 Volume 6, Issue 1 Volume 6, Issue 2 Volume 3, Issue 1 Volume 3, Issue 2 Volume 3, Issue 3 Volume 4, Issue 1 Volume 4, Issue 2 Volume 1, Issue 2 Volume 2, Issue 1 Volume 2, Issue 2 Volume 2, Issue 3 Volume 1, Issue 1